Endologix Appoints Vice President of Sales
July 16 2008 - 5:00PM
Business Wire
Endologix, Inc. (Nasdaq:ELGX), developer of the Powerlink� System
for the minimally invasive treatment of abdominal aortic aneurysms
(AAA), announces the appointment of Joseph A. DeJohn as Vice
President of Sales, effective immediately. Mr. DeJohn brings more
than 20 years of sales management experience in the medical device
industry, including serving in senior positions in the peripheral
vascular device division at C.R. Bard Corporation. �Joe brings a
strong track record of building and leading high-performing sales
teams in the vascular industry,� said John McDermott, Endologix
President and Chief Executive Officer. �From my experience working
with Joe, I can attest that he is a results-oriented leader with a
breadth of experience in hiring, training, developing and retaining
medical device sales professionals. We expect to tap Joe�s proven
capability to lead our sales force and gain market share with the
Powerlink System. Joe will be working with a talented and dedicated
sales management team that has successfully positioned Endologix
for solid continued growth. I am delighted to welcome him to our
senior management team.� During his 17-year tenure at C.R. Bard
Corporation, Mr. DeJohn held sales management positions with
increasing responsibilities, serving the past six years as Vice
President of Sales of the Peripheral Vascular Division. In this
position, he was responsible for driving revenues through his
management of a 200-person sales organization, playing a leadership
role in strategic planning, budgeting, recruitment, professional
development, national accounts and customer service. Prior to that,
he was Director of Sales of the Peripheral Technologies Division,
responsible for managing a 62-person sales organization and
implementing a substantial sales force expansion. Before joining
C.R. Bard Corporation, Mr. DeJohn served five years with Bausch
& Lomb Corporation in various sales management positions. He
received a B.S. in education from Bowling Green State University.
About Endologix Endologix, Inc. develops and manufactures minimally
invasive treatments for vascular diseases. Endologix's Powerlink
System is an endoluminal stent graft for treating abdominal aortic
aneurysms (AAA). AAA is a weakening of the wall of the aorta, the
largest artery in the body, resulting in a balloon-like
enlargement. Once AAA develops, it continues to enlarge and, if
left untreated, becomes increasingly susceptible to rupture. The
overall patient mortality rate for ruptured AAA is approximately
75%, making it a leading cause of death in the U.S. Additional
information can be found on Endologix�s Web site at
www.endologix.com. Except for historical information contained
herein, this news release contains forward-looking statements
relating to the continued growth of Endologix�s business and an
increasing share of the endovascular AAA market, the accuracy of
which are necessarily subject to risks and uncertainties, all of
which are difficult or impossible to predict accurately and many of
which are beyond the control of Endologix. The Company undertakes
no obligation to update its forward looking statements. Please
refer to the Company�s Annual Report on Form 10-K for the year
ended December 31, 2007, and the Company�s other filings with the
Securities and Exchange Commission, for more detailed information
regarding these risks and other factors that may cause actual
results to differ materially from those expressed or implied.
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Jul 2023 to Jul 2024